TaiMed Biologics is proud to announce that we have been selected by a U.S.-based client to provide contract manufacturing services for their antibody in clinical trials. This milestone marks our first international CDMO contract since launching our CDMO business. We are poised to sign the formal contract shortly, which will allow us to swiftly initiate the technology transfer, followed by rigorous analytical testing and production activities. We are excited to bring our expertise to this collaboration and contribute to the success of our client’s clinical trials.
TaiMed's successful bid represents a significant milestone, underscoring the company’s proficiency in securing substantial and trusted services from international clients. The advanced cGMP facility located in Zhubei, Taiwan, is equipped with bioreactors ranging from 50L to 2000L, enabling the production of both clinical and commercial-scale batches. The facility has repeatedly demonstrated its capability by producing numerous GMP/GLP batches of antibody drugs. Additionally, it successfully passed U.S. FDA inspections in both 2022 and 2023, achieving this without any 483s or major observations. With its cutting-edge equipment and considerable production capacity, TaiMed is ideally positioned to assist biotech companies with process development, technology transfer, scale-up, and GMP manufacturing services.